Search Videos by Topic or Participant
Browse by Series:

Immunotherapy in Renal Cell Carcinoma

Panelists: Janice P. Dutcher, MD, Cytokine Working Group; Robert A. Figlin, MD, Cedars-Sinai; Charles A. Henderson, MD, Peachtree Consultants; Daniel Heng,
Published: Thursday, Oct 16, 2014
For High-Definition, Click
There is growing interest regarding immunotherapy in the field of oncology, due particularly to the field’s new understanding of immune system modulation through the use of checkpoint inhibitors, comments Janice Dutcher, MD. These agents, such as anti-CTLA4 antibodies and anti-PD-L1 antibodies, allow the immune system to identify and exploit antigens that are tumor specific. Positive responses in renal cell carcinoma, melanoma, lung cancer, and prostate cancer have been demonstrated to date, suggesting that tumors may be more immunogenic than once believed.

Dutcher also comments on the therapeutic role of stereotactic radiation in combination with immunotherapy, which she designates as an under-explored area of research that requires further evaluation. This combination involves delivering local radiation to a targeted tumor to achieve an abscopal effect, or altering antigenic expression so that immunologic reactions may occur at sites that were not irradiated.
Slider Left
Slider Right
For High-Definition, Click
There is growing interest regarding immunotherapy in the field of oncology, due particularly to the field’s new understanding of immune system modulation through the use of checkpoint inhibitors, comments Janice Dutcher, MD. These agents, such as anti-CTLA4 antibodies and anti-PD-L1 antibodies, allow the immune system to identify and exploit antigens that are tumor specific. Positive responses in renal cell carcinoma, melanoma, lung cancer, and prostate cancer have been demonstrated to date, suggesting that tumors may be more immunogenic than once believed.

Dutcher also comments on the therapeutic role of stereotactic radiation in combination with immunotherapy, which she designates as an under-explored area of research that requires further evaluation. This combination involves delivering local radiation to a targeted tumor to achieve an abscopal effect, or altering antigenic expression so that immunologic reactions may occur at sites that were not irradiated.
View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Medical Crossfire®: Clinical Updates on PARP Inhibition and its Evolving Use in the Treatment of CancersMay 30, 20181.5
Publication Bottom Border
Border Publication
x